Pulmonary Fibrosis Treatment Market Size, Share, and Growth Forecast, 2026 - 2033

The global pulmonary fibrosis treatment market size is likely to be valued at US$3.7 billion in 2026 and is estimated to reach US$5.6 billion by 2033, growing at a CAGR of 6.2% during the forecast period 2026 − 2033, driven by an aging population, broader recognition of progressive fibrotic lung disease, regulatory expansion, and adoption of differentiated antifibrotic therapies.

Demographic aging increases the addressable patient pool as IPF is diagnosed predominantly among older adults. The U.S. population aged 65 and older reached 61.2 million in 2024, rising 3.1% from 2023, according to the U.S. Census Bureau. Regulatory activity is expanding treatment availability, with FDA approval of nerandomilast for IPF in October 2025 and PPF in December 2025. Technology adoption is shifting treatment toward targeted mechanisms, while specialist respiratory infrastructure and decentralized outpatient care support longer treatment pathways.

Driver - Aging Population and Rising Disease Recognition

Pulmonary fibrosis predominantly affects older adults, creating a demographic foundation for sustained treatment demand. U.S. Food and Drug Administration (U.S. FDA) information indicates that Idiopathic Pulmonary Fibrosis (IPF) is most diagnosed among people aged 60 to 70 years. Population aging is increasing the number of individuals entering age groups associated with a higher risk of chronic fibrotic lung disorders. This demographic shift supports greater demand for pulmonary evaluation and long-term disease management.

An aging population increases the number of individuals requiring pulmonary evaluation, lung-function monitoring, imaging, and long-term antifibrotic management. Greater recognition of progressive fibrotic phenotypes also improves identification of patients beyond classical IPF. Earlier referral to pulmonologists can increase treatment initiation and improve continuity of care. Improved awareness among physicians can further reduce delays between symptom onset, diagnosis, and treatment initiation. The effect is reinforced by expanding respiratory-care capacity, which supports diagnosis, monitoring, treatment adherence, and management of adverse events across chronic fibrotic lung conditions.

Regulatory Expansion and New Treatment Options

Regulatory activity is expanding the therapeutic addressable population by converting investigational mechanisms into commercially available treatment options. FDA approved Jascayd (nerandomilast) for adult IPF on October 7, 2025, representing the first new IPF therapy approved by FDA in more than a decade. FDA subsequently approved the therapy for adult PPF in December 2025. These approvals strengthen treatment availability for patients with progressive fibrotic disease and create new commercial pathways for pharmaceutical developers.

The expansion from IPF into PPF increases treatment opportunities across fibrotic interstitial lung diseases. EMA granted EU marketing authorization for Jascayd in July 2026 for both IPF and PPF, extending access within a major regulated pharmaceutical market. Such regulatory precedents can encourage pharmaceutical investment in differentiated antifibrotic mechanisms, combination approaches, and indication expansion. Broader indication coverage can improve the commercial viability of therapies by expanding eligible patient populations across multiple disease settings. Broader regulatory recognition also supports physician awareness and structured treatment pathways.

Restraint - Treatment Tolerability and Long-Term Adherence Constraints

Long-term treatment can be constrained by adverse-event management, dose adjustments, monitoring requirements, and patient tolerance. FDA documentation identifies notable tolerability issues associated with established antifibrotic therapies, including gastrointestinal effects and drug-induced liver injury. These factors can increase treatment-management requirements and affect persistence.

Complex monitoring can increase provider workload and healthcare-resource utilization. Dose interruptions or discontinuation can reduce realized treatment duration, limiting commercial scalability. New therapies must therefore demonstrate differentiated efficacy while maintaining manageable safety profiles to support sustained use.

Specialized Care Requirements and Supply-Chain Complexity

Pulmonary fibrosis management depends on specialized diagnosis, pulmonary-function assessment, imaging, oxygen support, and multidisciplinary clinical management. Limited access to specialist centers can delay diagnosis and treatment initiation, particularly where advanced respiratory infrastructure remains concentrated in major healthcare facilities.

Specialized manufacturing and distribution requirements can also affect scalability for emerging delivery systems. Inhaled therapies require device compatibility, patient training, and reliable product distribution. These requirements can increase commercialization costs and place pressure on margins when treatment adoption expands into less-developed healthcare networks.

Opportunity - Expansion of Therapies Across Progressive Pulmonary Fibrosis

PPF provides a clear pathway for market expansion because progressive fibrotic disease extends beyond idiopathic pulmonary fibrosis. FDA describes PPF as an umbrella term covering progressive lung scarring across multiple interstitial lung diseases. Companies can pursue indication expansion by demonstrating efficacy across heterogeneous patient populations and developing treatment strategies that complement existing disease management.

The approval of nerandomilast for PPF provides a regulatory precedent for broader antifibrotic development. Pharmaceutical companies can use biomarker development, longitudinal lung-function monitoring, and differentiated clinical-trial designs to identify patients at risk of progression. Earlier identification can improve treatment initiation and create a larger addressable population across specialty respiratory practices.

Inhaled and Targeted Delivery Innovation

Inhaled treatment represents an actionable innovation pathway because direct pulmonary delivery can provide localized exposure while offering an alternative to conventional systemic administration. United Therapeutics reported positive phase 3 TETON-1 and TETON-2 results for nebulized Tyvaso in IPF, with statistically significant improvements in FVC relative to placebo. The company stated that the therapy remains investigational for IPF and is not FDA-approved for that indication.

Successful regulatory progression could diversify administration options and strengthen adoption among patients requiring differentiated treatment approaches. Device innovation can further support this pathway through easier administration, treatment adherence features, and improved patient usability. Companies can combine clinical development with specialist-center education and patient-support programs to accelerate uptake after regulatory approval.

Drug Type Insights

Pirfenidone is anticipated to secure around 45% of the pulmonary fibrosis treatment market share in 2026, reflecting established clinical use and broad physician familiarity. FDA records generic pirfenidone approvals for IPF, supporting wider availability. Teva and Accord received FDA approvals for pirfenidone tablets. Established prescribing experience supports continued adoption across diagnosed IPF patients.

Nintedanib is expected to be the fastest-growing segment, propelled by continued adoption among patients requiring established antifibrotic treatment and its use across broader progressive fibrotic disease settings. Its established clinical position and physician familiarity support sustained demand. Expansion of treatment awareness and earlier disease management can further increase uptake, particularly as diagnosis of progressive pulmonary fibrosis improves.

Route of Administration Insights

Oral is poised to dominate with a forecast market share of over 85% in 2026, powered by established treatment pathways, convenient administration, and physician familiarity. FDA specifies twice-daily oral dosing for nerandomilast. Jascayd expands oral treatment availability for both IPF and PPF, supporting outpatient management and broad specialist adoption.

Injectables are estimated to be the fastest-growing segment, fueled by emerging advanced delivery approaches and increasing interest in targeted administration. Development activity remains focused on improving therapeutic exposure and patient outcomes. United Therapeutics reported positive phase 3 findings for nebulized Tyvaso in IPF, demonstrating the potential of direct pulmonary delivery to diversify treatment options.

Indication Insights

Idiopathic pulmonary fibrosis (IPF) is likely to be the leading segment with a projected 72% of the market share in 2026 due to established diagnostic pathways, approved antifibrotic therapies, and sustained specialist demand. FDA identifies IPF as a serious progressive disease with limited treatment options. For example, nerandomilast received FDA approval for IPF in 2025.

Progressive pulmonary fibrosis (PPF) is anticipated to be the fastest-growing segment, fueled by expanded disease recognition, regulatory validation, and broader identification of progressive fibrosis across interstitial lung diseases. FDA approved nerandomilast for adults with PPF in December 2025. The FIBRONEER-ILD study enrolled 1,178 adults with PPF, supporting evidence generation for this expanding indication.

North America Pulmonary Fibrosis Treatment Market Trends

North America is expected to lead with an estimated 38% share in 2026, supported by advanced pulmonary care, specialist networks, established reimbursement systems, and strong diagnostic capacity. The region benefits from extensive ILD treatment centers and pulmonary-function testing infrastructure. Rising awareness of fibrotic lung diseases is improving diagnosis and referral rates, supporting treatment adoption across established respiratory-care networks.

U.S. Pulmonary Fibrosis Treatment Market Insights

The U.S. is projected to account for around 85% of the North America share in 2026, supported by extensive ILD centers, diagnostic capacity, and pharmaceutical investment. FDA approved Jascayd for IPF in October 2025. The approval expanded oral treatment availability and strengthened competition, while ongoing clinical programs support broader adoption of differentiated therapies across specialist practices and integrated specialty care.

Canada Pulmonary Fibrosis Treatment Market Insights

Canada is forecast to contribute around 15% of the North America share in 2026, supported by established respiratory services and specialist-led diagnosis. Provincial healthcare systems influence treatment, access, and reimbursement. Growing recognition of progressive fibrotic disease can increase referrals to ILD centers. Broader availability of approved antifibrotics can support treatment uptake across eligible patients nationally.

Europe Pulmonary Fibrosis Treatment Market Trends

Europe is projected to hold around 29% share in 2026, supported by aging demographics, specialist respiratory networks, and established pharmaceutical access. National reimbursement systems influence adoption across countries. Regulatory alignment can facilitate availability of innovative therapies. Increasing recognition of progressive fibrotic disease can strengthen diagnosis, monitoring, and treatment initiation across major European healthcare systems and networks.

Germany Pulmonary Fibrosis Treatment Market Insights

Germany is expected to account for around 29% of the Europe share in 2026, supported by specialist pulmonary centers, advanced diagnostics, and structured healthcare delivery. Reimbursement frameworks can influence therapy adoption. Growing use of multidisciplinary ILD management can improve treatment pathways. Pharmaceutical companies can strengthen uptake through evidence generation, specialist education, and patient-support programs across regions.

U.K. Pulmonary Fibrosis Treatment Market Insights

The U.K. is forecast to contribute around 15% of the Europe share in 2026, supported by specialist respiratory services and established clinical pathways. NICE recommendations influence treatment access and reimbursement decisions. Earlier recognition of progressive disease can increase specialist referrals. Companies can support adoption through health-economic evidence, clinical education, and integration with NHS respiratory services across established specialist centers.

Asia Pacific Pulmonary Fibrosis Treatment Market Trends

Asia Pacific is forecast to be the fastest-growing market, with an estimated 24% share in 2026, stimulated by expanding healthcare infrastructure, rising diagnostic capacity, aging populations, and improving specialist access. Japan and China represent important demand centers. Pharmaceutical companies can expand through local partnerships, regulatory submissions, patient-access programs, and investments in specialty respiratory services across major urban healthcare systems strategically.

China Pulmonary Fibrosis Treatment Market Insights

China is projected to contribute around 32% of the Asia Pacific share in 2026, supported by expanding tertiary hospitals, improving diagnostic capabilities, and wider specialist access. Increasing use of imaging and pulmonary-function testing can improve disease identification. Domestic pharmaceutical development and international participation can strengthen treatment availability, while healthcare expansion can extend access beyond major cities and urban healthcare capacity.

Japan Pulmonary Fibrosis Treatment Market Insights

Japan is expected to account for around 28% of the Asia Pacific share in 2026, supported by an aging population, established respiratory infrastructure, and strong specialist capacity. Regulatory review can influence access to new antifibrotics. Advanced hospitals support pulmonary-function testing and long-term monitoring. Pharmaceutical companies can use Japan for clinical development and specialty-care expansion nationally and strategically.

The global pulmonary fibrosis treatment market is moderately consolidated, with established antifibrotic products supported by companies such as Boehringer Ingelheim, Roche, and Genentech, while emerging therapies increase competitive intensity. Pirfenidone and nintedanib remain established treatment options, while regulatory approval of nerandomilast has introduced another approved therapy for IPF and PPF.

Competition is shifting toward differentiated mechanisms, expanded indications, improved tolerability, and alternative delivery technologies. United Therapeutics is advancing inhaled treprostinil for IPF, while established pharmaceutical companies continue to strengthen clinical evidence and lifecycle strategies. Key participants include Boehringer Ingelheim, F. Hoffmann-La Roche, Genentech, United Therapeutics, and Shionogi.

Key Industry Developments

• In July 2026, Celea Therapeutics completed a $180 million financing to advance deupirfenidone (LYT-100) and support the Phase 3 SURPASS-IPF trial for idiopathic pulmonary fibrosis.
• In April 2026, Cipla received U.S. FDA approval for nintedanib capsules in 100 mg and 150 mg strengths, expanding its respiratory portfolio for the treatment of idiopathic pulmonary fibrosis.